Prostate disorders : procurement of biomarkers and pharmaceuticals

Objective

we will procure biomarkers and pharmaceuticals for prostate disorders. About 1 in 4 men over 55 have lower urinary tract symptoms due to benign prostatic hyperplasia, and 1 in 10 a lifetime risk of prostate cancer. Prostate disorders are a growing major socio-economic challenge because of our ageing population. We are clinicians, scientists and industrialists with complementary expertise and proven ability to collaborate. We will use prostate samples that are clinically well-defined and proprietary (DATAS) and established (suppression subtractive hybridisation, proteomics) approaches to identify changes in gene expression. We will show in clinical and model systems that these changes are important for prostate pathogenesis, and develop diagnostic/prognostics biomarkers and therapeutics for the painful and debilitating disorders of the prostate.

Programme(s)

• FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Topic(s)

• 1.1.1.-6. - Key action The Ageing Population and Disabilities

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Address

Rue René Descartes 15
67084 Strasbourg
France

Participants (6)

EXONHIT THERAPEUTICS S.A.

France

Address

Boulevard Masséna, 65
75013 Paris

FORSCHUNGSZENTRUM KARLSRUHE GMBH - TECHNIK UND UMWELT

Germany

Address

Hermann Von Helmholtz Platz 1
76021 Karlsruhe

LEOPOLD-FRANZENS-UNIVERSITAET INNSBRUCK

Austria

Address

Anichstrasse 35
6020 Innsbruck

PROTEOSYS AG

Germany

Address

Kupferberterrasse 17-19
55116 Mainz

STICHTING KATHOLIEKE UNIVERSITEIT

Netherlands

Address

Geert Grooteplein 10
6500 HB Nijmegen

WEIZMANN INSTITUTE OF SCIENCE

Israel

Address

Herzl Street 26
76100 Rehovot